BioCentury | Sep 17, 2020
Product Development

Sept. 16 Quick Takes: AAT deficiency data lift Arrowhead; plus Metacrine’s IPO, Seer spinout and PDUFA dates for Niemann-Pick, burn therapies

...plans to submit an MAA to EMA for the therapy by year-end. June PDUFA date for Vericel...
...date is June 29, 2021.TARGETSHsp70 – heat shock protein 70 BC Staff NexoBrid (debrase gel dressing) arimoclomol (BRX-345, OR-01) ARO-AAT Vericel Corp. MediWound...
BioCentury | Jun 4, 2019
Company News

Management tracks: Vericel, Theravance, Eisai

...Cell therapy company Vericel Corp. (NASDAQ:VCEL) disclosed in an SEC filing that Daniel Orlando resigned as COO...
...Greyrock Biomedical Advisors. BioCentury Staff Carisma Therapeutics Inc. Dicerna Pharmaceuticals Inc. Eisai Co. Ltd. Fluidigm Corp. Nanobiotix S.A. Sigilon Therapeutics Inc. Theravance Biopharma Inc. Vericel Corp....
BioCentury | Aug 20, 2018
Company News

Management tracks: Athenex, Intra-Cellular

...affairs. He was associate VP of clinical development at Allergan plc. (NYSE:AGN). Cell therapy developer Vericel Corp....
BioCentury | Jun 8, 2018
Financial News

Vericel prices $75M follow-on

...Cell therapy developer Vericel Corp. (NASDAQ:VCEL) raised $74.8 million through the sale of 5 million shares at...
...Ladenburg Thalmann. The figures include the sale of a 750,000 share overallotment on June 5. Vericel...
...bone marrow containing adult stem and progenitor cells. Vericel Corp. (NASDAQ:VCEL), Cambridge, Mass. Paul Bonanos Epicel (Brand), Epicel (Other) MACI Vericel...
BioCentury | Jun 1, 2018
Financial News

Vericel raises $65M in upsized follow-on

...Cell therapy developer Vericel Corp. (NASDAQ:VCEL) raised $65 million through the sale of 5 million shares at...
...follow-on underwritten by Leerink, BTIG and Ladenburg Thalmann. The price is a 7% discount from Vericel's...
...stock slipped $0.50 to $13.45 on Thursday and was up $0.95 to $14.40 on Friday. Vericel...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Nov 9, 2017
Company News

Management tracks: Pfizer, Hansa

...SIX:NOVN). Neurology company Neuralstem Inc. (NASDAQ:CUR) hired David Recker as CMO. He is CMO of Vericel Corp....
BioCentury | Jul 27, 2017
Strategy

FDA’s regeneration

...approval to a regenerative medicine product, Carticel, an autologous cultured chondrocyte product now marketed by Vericel Corp....
...skin substitute developed using NIKS human keratinocytes Deep partial thickness burns Phase III May 10 Vericel Corp....
BioCentury | May 19, 2017
Company News

ICT gets rights to Vericel programs in Asia, including China

...exclusive rights in parts of Asia to develop and commercialize a portfolio of products from Vericel Corp....
...completed a Phase IIb trial to treat heart failure due to ischemic dilated cardiomyopathy (DCM). Vericel...
...and manufacturing. Vericel will issue Innovative a three-month warrant to purchase $5 million in shares. Vericel Corp....
BioCentury | Apr 10, 2017
Company News

Management tracks

...Kovacs will leave the company in mid-May. PTC is seeking a replacement. Cell therapy company Vericel Corp....
Items per page:
1 - 10 of 289
BioCentury | Sep 17, 2020
Product Development

Sept. 16 Quick Takes: AAT deficiency data lift Arrowhead; plus Metacrine’s IPO, Seer spinout and PDUFA dates for Niemann-Pick, burn therapies

...plans to submit an MAA to EMA for the therapy by year-end. June PDUFA date for Vericel...
...date is June 29, 2021.TARGETSHsp70 – heat shock protein 70 BC Staff NexoBrid (debrase gel dressing) arimoclomol (BRX-345, OR-01) ARO-AAT Vericel Corp. MediWound...
BioCentury | Jun 4, 2019
Company News

Management tracks: Vericel, Theravance, Eisai

...Cell therapy company Vericel Corp. (NASDAQ:VCEL) disclosed in an SEC filing that Daniel Orlando resigned as COO...
...Greyrock Biomedical Advisors. BioCentury Staff Carisma Therapeutics Inc. Dicerna Pharmaceuticals Inc. Eisai Co. Ltd. Fluidigm Corp. Nanobiotix S.A. Sigilon Therapeutics Inc. Theravance Biopharma Inc. Vericel Corp....
BioCentury | Aug 20, 2018
Company News

Management tracks: Athenex, Intra-Cellular

...affairs. He was associate VP of clinical development at Allergan plc. (NYSE:AGN). Cell therapy developer Vericel Corp....
BioCentury | Jun 8, 2018
Financial News

Vericel prices $75M follow-on

...Cell therapy developer Vericel Corp. (NASDAQ:VCEL) raised $74.8 million through the sale of 5 million shares at...
...Ladenburg Thalmann. The figures include the sale of a 750,000 share overallotment on June 5. Vericel...
...bone marrow containing adult stem and progenitor cells. Vericel Corp. (NASDAQ:VCEL), Cambridge, Mass. Paul Bonanos Epicel (Brand), Epicel (Other) MACI Vericel...
BioCentury | Jun 1, 2018
Financial News

Vericel raises $65M in upsized follow-on

...Cell therapy developer Vericel Corp. (NASDAQ:VCEL) raised $65 million through the sale of 5 million shares at...
...follow-on underwritten by Leerink, BTIG and Ladenburg Thalmann. The price is a 7% discount from Vericel's...
...stock slipped $0.50 to $13.45 on Thursday and was up $0.95 to $14.40 on Friday. Vericel...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Nov 9, 2017
Company News

Management tracks: Pfizer, Hansa

...SIX:NOVN). Neurology company Neuralstem Inc. (NASDAQ:CUR) hired David Recker as CMO. He is CMO of Vericel Corp....
BioCentury | Jul 27, 2017
Strategy

FDA’s regeneration

...approval to a regenerative medicine product, Carticel, an autologous cultured chondrocyte product now marketed by Vericel Corp....
...skin substitute developed using NIKS human keratinocytes Deep partial thickness burns Phase III May 10 Vericel Corp....
BioCentury | May 19, 2017
Company News

ICT gets rights to Vericel programs in Asia, including China

...exclusive rights in parts of Asia to develop and commercialize a portfolio of products from Vericel Corp....
...completed a Phase IIb trial to treat heart failure due to ischemic dilated cardiomyopathy (DCM). Vericel...
...and manufacturing. Vericel will issue Innovative a three-month warrant to purchase $5 million in shares. Vericel Corp....
BioCentury | Apr 10, 2017
Company News

Management tracks

...Kovacs will leave the company in mid-May. PTC is seeking a replacement. Cell therapy company Vericel Corp....
Items per page:
1 - 10 of 289